|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.10.25 - 13:03
|
Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29 (Business Wire)
|
|
|
Conference Call and Webcast Scheduled for 1:30 p.m. PTALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2025 financial results after the market close on Wednesday, October 29, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on October 29, 2025.
A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (International) and enter Conference ID 5255602. A replay will be archived on the company's website following completion of the call.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing nov...
|
|
|
|
|
|
|
|
|
|
|
22.09.25 - 23:24
|
Expert Outlook: Glaukos Through The Eyes Of 4 Analysts (Benzinga)
|
|
|
Latest Ratings for GKOS
DateFirmActionFromTo Feb 2022CitigroupMaintainsNeutral Feb 2022William BlairUpgradesMarket PerformOutperform Jan 2022Wells FargoUpgradesUnderweightEqual-Weight
View More Analyst Ratings for GKOS
View the Latest Analyst Ratings
read more...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.07.25 - 22:06
|
Glaukos Announces Second Quarter 2025 Financial Results (Business Wire)
|
|
|
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2025. Key highlights include:
Record net sales of $124.1 million in Q2 2025 increased 30% year-over-year on a reported basis and 29% year-over-year on a constant currency basis.
Glaucoma record net sales of $103.5 million in Q2 2025 increased 36% year-over-year.
U.S. Glaucoma record net sales of $72.3 million in Q2 2025 increased 45% year-over-year.
Gross margin of approximately 78% and non-GAAP gross margin of approximately 83% in Q2 2025.
Raised 2025 net sales guidance to $480 million to $486 million, compared to $475 million to $485 million previously.
“Our record second quarter results reflect a sustained growth acceleration in our business driven by successful global execution of our key strategic plan...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
